Benign Hematologic Conditions
Primary Immune Thrombocytopenia
Advarra IRB #H-44465/ Novartis #CVAY736Q12301 (VAYHIT2):: A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First Line Steroid Treatment (VAYHIT2) (pending IRB approval)